Semaglutide A GLP-1 receptor agonist that mimics a gut hormone to slow digestion and increase feelings of fullness
In a 3-week study in DIO mice, semaglutide dose-dependently reduced BW and suppressed food intake
These intertwined epidemics have previously been strongly associated with cardiovascular complications, but more recent research suggests that these metabolic conditions may further trigger or exacerbate malignancy (cancers)
Side effects are typically transient and manageable
Generic versions of Victoza and Saxenda are now available in some countries, but no generic liraglutide products are yet registered and available in South Africa
Incretin mimetics delay gastric emptying, enhance satiety, and reduce appetite through central nervous system effects, leading to reduced caloric intake and 26 kg weight loss on average